CN107375904A - β‑arrestin1在防治色素障碍性皮肤病中的应用 - Google Patents
β‑arrestin1在防治色素障碍性皮肤病中的应用 Download PDFInfo
- Publication number
- CN107375904A CN107375904A CN201710645738.7A CN201710645738A CN107375904A CN 107375904 A CN107375904 A CN 107375904A CN 201710645738 A CN201710645738 A CN 201710645738A CN 107375904 A CN107375904 A CN 107375904A
- Authority
- CN
- China
- Prior art keywords
- arrestin1
- medicine
- activity
- hnf4
- suppress
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Marine Sciences & Fisheries (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710645738.7A CN107375904B (zh) | 2017-08-01 | 2017-08-01 | β-arrestin1在防治色素障碍性皮肤病中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710645738.7A CN107375904B (zh) | 2017-08-01 | 2017-08-01 | β-arrestin1在防治色素障碍性皮肤病中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107375904A true CN107375904A (zh) | 2017-11-24 |
CN107375904B CN107375904B (zh) | 2020-11-27 |
Family
ID=60343296
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710645738.7A Active CN107375904B (zh) | 2017-08-01 | 2017-08-01 | β-arrestin1在防治色素障碍性皮肤病中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107375904B (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1970074A (zh) * | 2005-11-23 | 2007-05-30 | 中国科学院上海生命科学研究院 | β-抑制蛋白在制备治疗表观遗传相关疾病的药物中的应用 |
CN101370525A (zh) * | 2005-08-19 | 2009-02-18 | 艾博特公司 | 双重可变结构域免疫球蛋白及其用途 |
CN102187229A (zh) * | 2008-12-24 | 2011-09-14 | 株式会社芳珂 | 皱纹形成风险的评价方法 |
CN105209491A (zh) * | 2013-03-15 | 2015-12-30 | 艾伯维公司 | 针对TNFα的双重特异性结合蛋白 |
CN105267954A (zh) * | 2015-11-30 | 2016-01-27 | 上海市第一人民医院 | 肝细胞核因子HNF-1α、HNF-4α在制备预防或治疗宫内生长迟缓的药物中的应用 |
-
2017
- 2017-08-01 CN CN201710645738.7A patent/CN107375904B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101370525A (zh) * | 2005-08-19 | 2009-02-18 | 艾博特公司 | 双重可变结构域免疫球蛋白及其用途 |
CN1970074A (zh) * | 2005-11-23 | 2007-05-30 | 中国科学院上海生命科学研究院 | β-抑制蛋白在制备治疗表观遗传相关疾病的药物中的应用 |
CN102187229A (zh) * | 2008-12-24 | 2011-09-14 | 株式会社芳珂 | 皱纹形成风险的评价方法 |
CN105209491A (zh) * | 2013-03-15 | 2015-12-30 | 艾伯维公司 | 针对TNFα的双重特异性结合蛋白 |
CN105267954A (zh) * | 2015-11-30 | 2016-01-27 | 上海市第一人民医院 | 肝细胞核因子HNF-1α、HNF-4α在制备预防或治疗宫内生长迟缓的药物中的应用 |
Non-Patent Citations (3)
Title |
---|
JIA ZHOU等: "Neurokinin-1 receptor is a novel positive regulator of Wnt/β-catenin signaling in melanogenesis", 《ONCOTARGET》 * |
平锋锋等: "P物质-神经激肽 1 受体通路与白癜风", 《临床皮肤科杂志》 * |
裴钢等: "抑制还是转导:信号分子调节机体健康与疾病", 《生命科学》 * |
Also Published As
Publication number | Publication date |
---|---|
CN107375904B (zh) | 2020-11-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Han et al. | Small molecule-driven NLRP3 inflammation inhibition via interplay between ubiquitination and autophagy: implications for Parkinson disease | |
Liu et al. | Cinnamaldehyde suppresses NLRP3 derived IL-1β via activating succinate/HIF-1 in rheumatoid arthritis rats | |
CN104080454B (zh) | 用于抑制肌萎缩的方法 | |
Ebert et al. | Identification and small molecule inhibition of an activating transcription factor 4 (ATF4)-dependent pathway to age-related skeletal muscle weakness and atrophy | |
Yan | Activation of 5-HT2A/2C receptors within the nucleus accumbens increases local dopaminergic transmission | |
EP2914619B1 (en) | Erythroferrone and erfe polypeptides and methods of regulating iron metabolism | |
Chang et al. | Plecanatide-mediated activation of guanylate cyclase-C suppresses inflammation-induced colorectal carcinogenesis in Apc+/Min-FCCC mice | |
Zhou et al. | Comparison and evaluation of antimuscarinic and anti-inflammatory effects of five Bulbus fritillariae species based on UPLC-Q/TOF integrated dual-luciferase reporter assay, PCA and ANN analysis | |
Lu et al. | Iminostilbene, a novel small-molecule modulator of PKM2, suppresses macrophage inflammation in myocardial ischemia–reperfusion injury | |
Laurila et al. | Inhibition of sphingolipid de novo synthesis counteracts muscular dystrophy | |
Ma et al. | Methanol extract of Longanae Arillus augments pentobarbital-induced sleep behaviors through the modification of GABAergic systems | |
Iwata et al. | Protective effect of d-alanine against acute kidney injury | |
Zhang et al. | A purified biflavonoid extract from selaginella moellendorffii alleviates gout arthritis via NLRP3/ASC/Caspase-1 axis suppression | |
Wang et al. | FPS-ZM1 inhibits LPS-induced microglial inflammation by suppressing JAK/STAT signaling pathway | |
Zhang et al. | Lipopolysaccharide‐induced proliferation and glycolysis in airway smooth muscle cells via activation of Drp1 | |
Liu et al. | A new LKB1 activator, piericidin analogue S14, retards renal fibrosis through promoting autophagy and mitochondrial homeostasis in renal tubular epithelial cells | |
Guo et al. | Flavonoid‐Like Components of Peanut Stem and Leaf Extract Promote Sleep by Decreasing Neuronal Excitability | |
Li et al. | The chemokine-like factor 1 induces asthmatic pathological change by activating nuclear factor-κB signaling pathway | |
Di et al. | Novel clerodane-type diterpenoid Cintelactone A suppresses lipopolysaccharide-induced inflammation by promoting ubiquitination, proteasomal degradation of TRAF6 | |
Tanaka et al. | Huaier regulates cell fate by the rescue of disrupted transcription control in the Hippo signaling pathway | |
Wang et al. | Using molecular docking screening for identifying hyperoside as an inhibitor of fatty acid binding protein 4 from a natural product database | |
Ogura et al. | Prenylated quinolinecarboxylic acid derivative suppresses immune response through inhibition of PAK2 | |
Jeong et al. | Anti-inflammatory Activity of an Ethanol Extract of Caesalpinia sappan L. in LPS-induced RAW 264.7 Cells | |
CN107375904A (zh) | β‑arrestin1在防治色素障碍性皮肤病中的应用 | |
You et al. | Inonotus obliquus upregulates muscle regeneration and augments function through muscle oxidative metabolism |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Ping Fengfeng Inventor after: Jiang Lijie Inventor after: Other inventor requests not to publish the name Inventor after: Zhu Lihong Inventor after: Ling Jingjing Inventor after: Lv Bei Inventor after: Qian Jun Inventor after: Wang Lei Inventor after: Xia Xiaoai Inventor after: Du Yali Inventor after: Ren Chunxia Inventor before: Ping Fengfeng Inventor before: Fang Yanna Inventor before: Ling Jingjing Inventor before: Lv Bei Inventor before: Qian Jun Inventor before: Wang Lei Inventor before: Xia Xiaoai Inventor before: Du Yali Inventor before: Ren Chunxia Inventor before: Jiang Lijie |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20221123 Address after: Room 401, Zone B, Floor 4, Building A8, No. 8, Bailongjiang East Street, Jianye District, Nanjing City, Jiangsu Province, 210000 Patentee after: Nanjing Chuang'ao Biotechnology Co.,Ltd. Address before: 214023 Qingyang Road 299, Wuxi City, Jiangsu Province Patentee before: Wuxi People's Hospital |